| Item Type | Name |
|
Academic Article
|
Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.
|
|
Academic Article
|
Second International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: summary consensus statement.
|
|
Academic Article
|
Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer.
|
|
Academic Article
|
Statistical analysis of array expression data as applied to the problem of tamoxifen resistance.
|
|
Academic Article
|
Spreading the word, but not too thinly.
|
|
Academic Article
|
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.
|
|
Academic Article
|
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
|
|
Academic Article
|
Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo.
|
|
Academic Article
|
Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
|
|
Academic Article
|
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials.
|
|
Academic Article
|
Aromatase inhibitors: future directions.
|
|
Academic Article
|
Scaffold attachment factor SAFB1 suppresses estrogen receptor alpha-mediated transcription in part via interaction with nuclear receptor corepressor.
|
|
Academic Article
|
Morphologic and immunophenotypic markers as surrogate endpoints of tamoxifen effect for prevention of breast cancer.
|
|
Academic Article
|
Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials.
|
|
Academic Article
|
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.
|
|
Academic Article
|
Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.
|
|
Academic Article
|
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
|
|
Academic Article
|
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
|
|
Academic Article
|
Low levels of estrogen receptor beta protein predict resistance to tamoxifen therapy in breast cancer.
|
|
Academic Article
|
Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial.
|
|
Academic Article
|
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
|
|
Academic Article
|
Endocrinology and hormone therapy in breast cancer: new insight into estrogen receptor-alpha function and its implication for endocrine therapy resistance in breast cancer.
|
|
Academic Article
|
Optimizing chemotherapy-free survival for the ER/HER2-positive metastatic breast cancer patient.
|
|
Academic Article
|
Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
|
|
Academic Article
|
Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
|
|
Academic Article
|
Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
|
|
Academic Article
|
Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.
|
|
Academic Article
|
Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.
|
|
Academic Article
|
Mechanisms of endocrine resistance in breast cancer.
|
|
Academic Article
|
Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial.
|
|
Academic Article
|
Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.
|
|
Academic Article
|
Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
|
|
Academic Article
|
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.
|
|
Concept
|
Antineoplastic Agents, Hormonal
|
|
Academic Article
|
Aromatase inhibitors in the treatment of advanced breast cancer. Introduction.
|
|
Academic Article
|
Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896.
|
|
Academic Article
|
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survival.
|
|
Academic Article
|
bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group study.
|
|
Academic Article
|
Comparison of estrogen receptor DNA binding in untreated and acquired antiestrogen-resistant human breast tumors.
|
|
Academic Article
|
Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
|
|
Academic Article
|
Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial.
|
|
Academic Article
|
Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer: an intergroup study.
|
|
Academic Article
|
Heat shock proteins hsp27 and hsp70: lack of correlation with response to tamoxifen and clinical course of disease in estrogen receptor-positive metastatic breast cancer (a Southwest Oncology Group Study).
|
|
Academic Article
|
Tamoxifen in the treatment of breast cancer.
|
|
Academic Article
|
Prediction of clinical outcome from primary tamoxifen by expression of biologic markers in breast cancer patients.
|
|
Academic Article
|
Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement.
|
|
Academic Article
|
Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials.
|
|
Academic Article
|
Postmenopausal women who progress on fulvestrant ('Faslodex') remain sensitive to further endocrine therapy.
|
|
Academic Article
|
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.
|